Centre for Eye and Vision Research

CEVR Conducts Translational Research to Prevent, Detect, Treat and Mitigate Vision Loss

Centre for Eye and Vision Research (CEVR), co-founded by The Hong Kong Polytechnic University and the University of Waterloo (Canada), is a core laboratory under the HKSAR Government’s InnoHK initiative. CEVR aims to be a world-leading translational vision hub, pioneering three core areas: 1) Preserving and Restoring Vision Health, 2) Next-Generation Therapeutics, and 3) Advanced Optometric Technologies. Leveraging internationally award-winning research, patent breakthroughs, and clinical-grade infrastructure, CEVR successfully bridges academic discovery and commercial clinical application, delivering revolutionary advancements to global ophthalmic care, improving vision health and quality of life.

CEVR hosts state-of-the-art clinical research and vision examination facilities, equipped with advanced diagnostic technologies to support world-class translational vision science.

Advanced mass spectrometry and Ultra-Performance Liquid Chromatography (UPLC) platforms in CEVR’s bioscience laboratory, utilized for deep molecular analysis and the development of innovative ocular therapeutics.

Commercialized via the CEVR’s spin-off Entoptica, the Structured Light Observation and Perception Evaluation (SLOPE) device utilizes advanced quantum optical technology to assess macular health.

The CEVR projects received prestigious international accolades at the 49th - 51st International Exhibition of Inventions Geneva, highlighting our commitment to world-class innovation and global health impact.

Entoptica, a spin-off company from CEVR, and its flagship Structured Light Observation and Perception Evaluation (SLOPE) device, won the Information Technology Startup Grand Award at the Hong Kong ICT Awards 2025. This achievement demonstrates the Centre’s ability to successfully translate laboratory research into market-ready commercial solutions.

CEVR’s research programmes span a comprehensive pipeline covering three major areas: preserving and restoring healthy vision, next-generation therapeutics, and advanced optometric technologies. Key initiatives include AI-assisted imaging for early and non-invasive detection of eye diseases, anti-myopia display technologies to protect children’s vision, and neuromodulation approaches to enhance visual function. The Centre is advancing innovative solutions such as gene and nanoparticle-based drug delivery systems, Eye-on-a-Chip technology for accelerated drug testing, and precision treatments for conditions including glaucoma and dry eye disease. Advanced technologies such as tear-based diagnostics, structured light ocular screening, and extended reality systems aim to improve early detection, accessibility, and independence for patients. Together, these have strong potential to transform the prevention, detection, treatment and mitigation of vision loss. Leveraging Hong Kong’s strong talent pool, world-class R&D infrastructure, and strategic access to the Mainland and Greater Bay Area, CEVR facilitates collaboration and translation into real-world solutions with global impact.